These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37500316)

  • 1. Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: Exploring the Role of Genotype-Guided Therapy in Reducing Readmission Rates.
    Comanici M; Raja SG
    Am J Cardiol; 2023 Sep; 203():507-508. PubMed ID: 37500316
    [No Abstract]   [Full Text] [Related]  

  • 2. CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention.
    Williams AK; Klein MD; Martin J; Weck KE; Rossi JS; Stouffer GA; Lee CR
    Circ Genom Precis Med; 2019 Feb; 12(2):e002441. PubMed ID: 30779635
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
    Klein MD; Williams AK; Lee CR; Stouffer GA
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.
    Wang Y; Yan BP; Liew D; Lee VWY
    Pharmacogenomics J; 2018 Jan; 18(1):113-120. PubMed ID: 28117433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a benefit for
    van den Broek WW; Ten Berg JM
    Pharmacogenomics; 2021 Aug; 22(12):727-730. PubMed ID: 34251288
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
    Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
    Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
    AlMukdad S; Elewa H; Al-Badriyeh D
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
    Gross L; Trenk D; Jacobshagen C; Krieg A; Gawaz M; Massberg S; Baylacher M; Aradi D; Stimpfle F; Hromek J; Vogelgesang A; Hadamitzky M; Sibbing D; Geisler T
    Thromb Haemost; 2018 Sep; 118(9):1656-1667. PubMed ID: 30103241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention.
    Cheng KK; San Andres C; Salam E; Han J; Lee JC
    Am J Cardiol; 2023 Sep; 202():218-222. PubMed ID: 37473671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective
    Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
    Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Another Step Toward CYP2C19 Genotype-Guided Therapy in Treatment With Dual Antiplatelet Therapy.
    Ten Berg JM; van den Broek WWA
    JACC Cardiovasc Interv; 2023 Apr; 16(7):826-828. PubMed ID: 37045503
    [No Abstract]   [Full Text] [Related]  

  • 12. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
    Johnson SG; Gruntowicz D; Chua T; Morlock RJ
    J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Lyu SQ; Yang YM; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Ren JM
    Platelets; 2020 Nov; 31(8):971-980. PubMed ID: 32546030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.
    Klein MD; Lee CR; Stouffer GA
    Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.
    Borse MS; Dong OM; Polasek MJ; Farley JF; Stouffer GA; Lee CR
    Pharmacogenomics; 2017 Aug; 18(12):1155-1166. PubMed ID: 28745582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Gender on Clinical Outcomes in Patients Receiving
    Gustafson C; Gower MN; Williams AK; Pauley E; Weck KE; Lee CR; Stouffer GA
    Circ Genom Precis Med; 2020 Oct; 13(5):554-556. PubMed ID: 32938199
    [No Abstract]   [Full Text] [Related]  

  • 18. Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y
    Xi Z; Wang Y; Lu Q; Qiu H; Gao Y; Gao A; Gao R
    Thromb Res; 2023 Aug; 228():85-93. PubMed ID: 37301117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
    JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-Guided Antiplatelet Therapy After Coronary Intervention in Patients With High Bleeding Risk　- Never Judge a Book by Its Cover.
    Iijima R
    Circ J; 2023 May; 87(6):764-766. PubMed ID: 37032075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.